DSM-Firmenich AG

Chart & Performance

D1W1MN

P/E

9.37

P/S

0.18

EPS

0.94

Div Yield, %

—

Shrs. gr., 5y

8.40%

Rev. gr., 5y

9.86%

Revenues

12.80b

+20.44%

Net income

250m

CFO

1.78b

+40.55%

Earnings

Jul 28, 2025

Profile

DSM-Firmenich AG, a science-based company, engages in beauty, health, and nutrition businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Perfumery & Beauty; Animal Nutrition & Health (ANH); Health, Nutrition & Care (HNC); and Food & Beverage segments. The Perfumery & Beauty offers perfumery and aroma ingredients. The Animal Nutrition & Health segment offers essential products, including vitamins, premixes, and carotenoids; performance solutions, such as enzymes, microbes, and eubiotics; precision services comprising support with data analysis to measure animal health and environmental footprint on farm level and feed safety; and methane reducing feed additive for ruminants. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, personal care and aroma, and biomedical materials markets. It offers vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics and prebiotics, active pharmaceutical ingredients, and sunscreen filters, as well as a range of biomedical solutions; premix, market-ready solutions, and personalized nutrition solutions; and regulatory affairs and formulation expertise, and customized solutions. The Food & Beverage segment provides ingredients and solutions for use in a range of food products, such as dairy; bakery, cereals, and bars; savory food; beverages and brewing; confectionery and fruit; plant-based meat and fish alternatives; and petfood. The company was founded in 1902 and is headquartered in Kaiseraugst, Switzerland.

URL

https://www.dsm-firmenich.com

IPO date

Apr 18, 2023

Employees

29,306

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	12,799,000 20.44%	10,627,000 26.66%	8,390,000 -26.69%
Cost of revenue	8,554,000	11,195,000	7,673,000
Unusual Expense (Income)
NOPBT	4,245,000	(568,000)	717,000
NOPBT Margin	33.17%		8.55%
Operating Taxes	147,000	(18,000)	124,000
Tax Rate	3.46%		17.29%
NOPAT	4,098,000	(550,000)	593,000
Net income	250,000 -138.34%	(652,000) -241.74%	460,000 -47.25%
Dividends	(667,000)	(582,000)	(345,000)
Dividend yield	2.58%	2.71%
Proceeds from repurchase of equity	(685,000)	501,000	(160,000)
BB yield	2.65%	-2.34%
Debt
Debt current	836,000	716,000	86,000
Long-term debt	4,444,000	4,529,000	2,978,000
Deferred revenue		70,000	25,000
Other long-term liabilities	690,000	746,000	601,000
Net debt	2,271,000	1,815,000	(254,000)
Cash flow
Cash from operating activities	1,778,000	1,265,000	923,000
CAPEX	(764,000)	(555,000)	(644,000)
Cash from investing activities	(252,000)	(795,000)	871,000
Cash from financing activities	(1,334,000)	(820,000)	(598,000)
FCF	3,796,000	(2,402,000)	(90,000)
Balance
Cash	2,717,000	2,563,000	2,880,000
Long term investments	292,000	867,000	438,000
Excess cash	2,369,050	2,898,650	2,898,500
Stockholders' equity	186,000	11,383,000	10,570,000
Invested Capital	28,481,000	25,817,350	11,492,500
ROIC	15.09%		5.07%
ROCE	14.05%		4.76%
EV
Common stock shares outstanding	264,600	233,200	173,300
Price	97.72 6.22%	92.00
Market cap	25,856,712 20.52%	21,454,400
EV	28,313,712	23,431,400
EBITDA	4,245,000	739,000	1,369,000
EV/EBITDA	6.67	31.71
Interest		166,000	70,000
Interest/NOPBT			9.76%